{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:51:37Z","timestamp":1791384697362,"version":"4.3.3"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ncl.2020.01.010","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T08:56:37Z","timestamp":1583744197000},"page":"367-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Medical, Surgical, and Genetic Treatment of Huntington Disease"],"prefix":"10.1016","volume":"38","author":[{"given":"Christine M.","family":"Stahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Feigin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2020.01.010_bib1","unstructured":"Huntington G. On chorea. The medical surgical reporter: a weekly journal. The Medical Surgical Reporter 1872;26(15):317\u201321."},{"key":"10.1016\/j.ncl.2020.01.010_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A\u00a0novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The\u00a0Huntington's Disease\u00a0Collaborative Research Group","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ncl.2020.01.010_bib3","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ncl.2020.01.010_bib4","first-page":"1243","article-title":"ACMG\/ASHG\u00a0statement.\u00a0Laboratory\u00a0guidelines\u00a0for\u00a0Huntington disease\u00a0genetic testing. The American College of Medical Genetics\/American Society of Human Genetics\u00a0Huntington Disease\u00a0Genetic Testing\u00a0Working Group","volume":"62","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ncl.2020.01.010_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2019.05.010","article-title":"Clinical phenotype in carriers of intermediate alleles in the huntingtin gene","volume":"402","author":"Savitt","year":"2019","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2020.01.010_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington's disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ncl.2020.01.010_bib7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng0893-398","article-title":"The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease","volume":"4","author":"Andrew","year":"1993","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.010_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ncl.2020.01.010_bib9","doi-asserted-by":"crossref","first-page":"RRN1293","DOI":"10.1371\/currents.RRN1293","article-title":"Aspiration pneumonia and death in Huntington's disease","volume":"4","author":"Heemskerk","year":"2012","journal-title":"PLoS Curr"},{"key":"10.1016\/j.ncl.2020.01.010_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2018.09.022","article-title":"Huntington disease: a quarter century of progress since the gene discovery","volume":"396","author":"Testa","year":"2019","journal-title":"J\u00a0Neurol Sci"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.010_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1755-5949.2010.00134.x","article-title":"Dopamine and glutamate in Huntington's disease: a balancing act","volume":"16","author":"Andre","year":"2010","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.010_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11910-017-0739-9","article-title":"Huntington's disease-update on treatments","volume":"17","author":"Wyant","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"11","key":"10.1016\/j.ncl.2020.01.010_bib13","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.25996","article-title":"Chorea associated with Huntington's disease: to treat or not to treat?","volume":"29","author":"Jankovic","year":"2014","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.010_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2020.01.010_bib15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders","volume":"11","author":"Jankovic","year":"2011","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.010_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group","volume":"11","year":"1996","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.010_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/mds.25278","article-title":"Analysis of CYP2D6 genotype and response to tetrabenazine","volume":"28","author":"Mehanna","year":"2013","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.010_bib18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/NMD.0b013e3181da852a","article-title":"Comorbidities of obsessive and compulsive symptoms in Huntington's disease","volume":"198","author":"Anderson","year":"2010","journal-title":"J\u00a0Nerv Ment Dis"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.010_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with huntington disease: a randomized clinical trial","volume":"316","author":"Huntington Study Group","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ncl.2020.01.010_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J\u00a0Clin Mov Disord"},{"key":"10.1016\/j.ncl.2020.01.010_bib21","doi-asserted-by":"crossref","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","article-title":"An international survey-based algorithm for the pharmacologic treatment of chorea in huntington's disease","volume":"3","author":"Burgunder","year":"2011","journal-title":"PLoS Curr"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.010_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in huntington's disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.010_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14737175.2018.1403899","article-title":"Treatment options for chorea","volume":"18","author":"Bashir","year":"2018","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.010_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ncl.2020.01.010_bib25","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mds.25500","article-title":"Pharmacological treatment of chores in Hungtington\u2019s disease - good clinical practice versus evidence-based guildline","volume":"28","author":"Reilmann","year":"2013","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.010_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0404.1982.tb03060.x","article-title":"Tiapride in the treatment of Huntington's chorea","volume":"65","author":"Roos","year":"1982","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"10.1016\/j.ncl.2020.01.010_bib27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/03007998409109601","article-title":"Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea","volume":"9","author":"Deroover","year":"1984","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.ncl.2020.01.010_bib28","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/mds.22188","article-title":"A\u00a0Europe-wide assessment of current medication choices in Huntington's disease","volume":"23","author":"Priller","year":"2008","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.010_bib29","article-title":"Risperidone versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.010_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mdc3.12706","article-title":"Comparing risperidone and olanzapine to tetrabenazine for the management of chorea in huntington disease: an analysis from the enroll-HD database","volume":"6","author":"Schultz","year":"2019","journal-title":"Mov Disord Clin Pract"},{"issue":"11","key":"10.1016\/j.ncl.2020.01.010_bib31","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study","volume":"61","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.010_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington's disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2020.01.010_bib33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study","volume":"56","author":"Metman","year":"1999","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2020.01.010_bib34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","article-title":"A\u00a0randomized trial of amantadine in Huntington disease","volume":"60","author":"O'Suilleabhain","year":"2003","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.010_bib35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2011.10.021","article-title":"An evidence-based approach in the treatment of Huntington's disease","volume":"18","author":"Mestre","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.010_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.01.010_bib37","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.ncl.2020.01.010_bib38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1212\/01.WNL.0000052992.58107.67","article-title":"Predictors of nursing home placement in Huntington disease","volume":"60","author":"Wheelock","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.01.010_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-0-444-63916-5.00016-1","article-title":"Gait, balance, and falls in Huntington disease","volume":"159","author":"Vuong","year":"2018","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2020.01.010_bib40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1468-1331.2012.03760.x","article-title":"Physical therapy in Huntington's disease--toward objective assessments?","volume":"20","author":"Bohlen","year":"2013","journal-title":"Eur J Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2020.01.010_bib41","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S2215-0366(16)30144-4","article-title":"Changes in mental state and behaviour in Huntington's disease","volume":"3","author":"Eddy","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ncl.2020.01.010_bib42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/B978-0-12-801893-4.00011-0","article-title":"Medical treatment of behavioral manifestations of Huntington disease","volume":"144","author":"van Duijn","year":"2017","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.010_bib43","first-page":"355","article-title":"Clinical management of neuropsychiatric symptoms of huntington disease: expert-based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders","volume":"7","author":"Anderson","year":"2018","journal-title":"J\u00a0Huntingtons Dis"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.010_bib44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2217\/nmt-2016-0007","article-title":"Brain stimulation in Huntington's disease","volume":"6","author":"Hartmann","year":"2016","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.ncl.2020.01.010_bib45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fneur.2015.00177","article-title":"A\u00a0prospective pilot trial for pallidal deep brain stimulation in huntington's disease","volume":"6","author":"Wojtecki","year":"2015","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.010_bib46","first-page":"114","article-title":"Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study","volume":"121","author":"Gonzalez","year":"2014","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.ncl.2020.01.010_bib47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2018.02.030","article-title":"Prospective evaluation of Globus pallidus internus deep brain stimulation in Huntington's disease","volume":"51","author":"Zittel","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"10.1016\/j.ncl.2020.01.010_bib48","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00702-014-1201-7","article-title":"Quadruple deep brain stimulation in Huntington's disease, targeting pallidum and subthalamic nucleus: case report and review of the literature","volume":"121","author":"Gruber","year":"2014","journal-title":"J\u00a0Neural Transm (Vienna)"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.010_bib49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.ncl.2020.01.010_bib50","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1111\/febs.12418","article-title":"Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis","volume":"280","author":"Lee","year":"2013","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.010_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ncl.2020.01.010_bib52","first-page":"1","article-title":"Emerging therapies in Huntington's disease","author":"Bashir","year":"2019","journal-title":"Expert Rev Neurother"},{"issue":"24","key":"10.1016\/j.ncl.2020.01.010_bib53","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2020.01.010_bib54","first-page":"65","article-title":"The biological function of the Huntingtin protein and its relevance to Huntington's disease pathology","volume":"5","author":"Schulte","year":"2011","journal-title":"Curr Trends Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.010_bib55","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ymthe.2018.02.002","article-title":"Translation of MicroRNA-based huntingtin-lowering therapies from preclinical studies to the clinic","volume":"26","author":"Miniarikova","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.ncl.2020.01.010_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","article-title":"Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease","volume":"76","author":"Southwell","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.010_bib57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jnnp.65.4.577","article-title":"Levodopa responsive parkinsonism in an adult with Huntington's disease","volume":"65","author":"Racette","year":"1998","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2020.01.010_bib58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0303-8467(80)90017-7","article-title":"Seven cases of Huntington's disease in childhood and levodopa induced improvement in the hypokinetic--rigid form","volume":"82","author":"Jongen","year":"1980","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.ncl.2020.01.010_bib59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200201000-00011","article-title":"Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.ncl.2020.01.010_bib60","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions","author":"Li","year":"2015","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:20:32Z","timestamp":1760005232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861920300104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0733861920300104"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2020.01.010","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical, Surgical, and Genetic Treatment of Huntington Disease","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2020.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}